In the last few years, Immune checkpoint inhibitors (ICIs) are a new class of immunotherapy drugs that are beneficial for treating different types of cancers like metastatic melanoma, non-small lung cancer, or renal cell carcinoma. These drugs work by blocking checkpoint proteins from binding with their partner proteins.
But, the immune checkpoint inhibitor-associated myocarditis has led to a significant and possibly deadly side-effect. Hence, identifying, diagnosing, and managing ICI-associated myocarditis has created new difficulties for the practicing medical professional.
In this study Lehmann L et. al conducted a current literature review on ICI-associated myocarditis with an aim to provide a standardized diagnostic and therapeutic approach for patients with suspected ICI-associated myocarditis.
· The researchers observed that the clinical presentation and cardiac pathological findings are greatly variable in patients with ICI-associated myocarditis.
· And though endomyocardial biopsy is a standard diagnostic test, a combination of clinical suspicion, cardiac biomarkers (specifically troponin), and cardiac imaging, in addition to a biopsy are generally required to support the diagnosis.
· Lastly, the combination of a cytotoxic T-lymphocyte-associated protein 4 inhibitors with a programmed cell death protein 1 or programmed death-ligand 1 inhibitor increases the risk of developing ICI-associated myocarditis.
The researchers concluded that a complete history of recent cancer treatments and physical examination in combination with cardiac biomarkers, cardiac imaging, and endomyocardial biopsy represent a pragmatic diagnostic approach for most cases of ICI-associated myocarditis. Also, the addition of novel biomarkers or imaging modalities is an area of active research and should be evaluated within the larger cohorts.
Reference:
A study titled, "Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis: A Narrative Review" by Lehmann L et. al published in the JAMA Cardiol.
DOI:10.1001/jamacardio.2021.2241
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.